Skip to Content

Phentolamine Pregnancy and Breastfeeding Warnings

Phentolamine is also known as: OraVerse, Regitine

Phentolamine Pregnancy Warnings

Phentolamine has been assigned to pregnancy category C by the FDA. Animal data have revealed slightly decreased growth and slight skeletal immaturity of the fetuses after rats and mice were given doses 24 to 30 times the usual daily human doses (UDHD, on a per kg basis). At oral doses 60 times the UDHD (on a per kg basis), a slightly lower rate of implantation was found in the rat. Phentolamine did not affect embryonic or fetal development in the rabbit at oral doses 20 times the UDHD. No teratogenic or embryotoxic effects were observed in any of the animal studies. There are no reports of adverse effects on the fetus from isolated cases in which the drug has been used to treat pheochromocytoma during human pregnancy. There are no controlled in human pregnancy. Phentolamine is only recommended for use during pregnancy when benefit outweighs risk.

The relationship between with the use of phentolamine and maternal or fetal mortality in patients with pheochromocytoma is not clear because of the significant mortality associated with this tumor. Some experts recommend caution if phentolamine must be used during pregnancy because of the risk of hypotension and decreased placental perfusion pressure. Use of this drug during pregnancy should, therefore, be limited to the treatment of acute episodes of hypertension in patients with pheochromocytoma and for the immediate preoperative and intraoperative management of such a patient undergoing Cesarean section and/or removal of the pheochromocytoma. Phentolamine is not recommended as a diagnostic agent during pregnancy because of the availability of safer methods (urinary catecholamine levels). It is also not recommended for the chronic management of pheochromocytoma during pregnancy. Phentolamine does not appear to adversely affect uterine contractility. Animal studies have revealed evidence of skeletal immaturity associated with phentolamine. Immaturity was manifested by an increased incidence of incomplete or unossified calcaei and phalangeal nuclei of the hind limb and of incompletely ossified sternabrae.

Phentolamine Breastfeeding Warnings

There are no data on the excretion of phentolamine into human milk. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.